Pacira director granted stock and option awards

Pacira BioSciences director Mark Froimson received equity compensation consisting of restricted stock units and stock options.

Rhea-AI Filing Summary

Pacira BioSciences director Mark Froimson received equity compensation consisting of restricted stock units and stock options. He was granted 6,405 restricted stock units, each representing the right to receive one share of Pacira common stock. These units vest on June 10, 2027, if he remains in continuous service through that date, and will then convert into common shares.

He was also granted 10,891 stock options to buy Pacira common stock at an exercise price of $23.42 per share. These options vest and become exercisable on June 10, 2027, subject to the same continuous service condition, and expire on June 10, 2036. Following the grant, Froimson directly holds 26,541 shares of Pacira common stock.

Insider Trade Summary

Grant/Award: 17,296 shares

Grant/Award 2 txns

Insider Froimson Mark

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,891	$0.00	$0.00
Grant/Award	Common Stock	6,405	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,891 contracts (Direct); Common Stock — 26,541 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
2. F2. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Key Figures

Restricted stock units granted: 6,405 units Stock options granted: 10,891 options Option exercise price: $23.42 per share +3 more

6 metrics

Restricted stock units granted 6,405 units Vest on June 10, 2027, into common shares

Stock options granted 10,891 options Grant of options to buy Pacira common stock

Option exercise price $23.42 per share Exercise price for 10,891 stock options

Option vesting date June 10, 2027 Stock options vest and become exercisable on this date

Option expiration date June 10, 2036 Expiration of newly granted stock options

Shares held after grant 26,541 shares Direct Pacira common stock ownership following RSU grant

Key Terms

restricted stock units, stock option, continuous service, Grant, award, or other acquisition

4 terms

restricted stock units financial

"Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock option financial

"The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

continuous service financial

"provided that the reporting person remains in continuous service with the issuer through the vesting date"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Pacira (PCRX) director Mark Froimson receive?

Mark Froimson received 6,405 restricted stock units and 10,891 stock options as equity compensation. The restricted units convert into common shares at vesting, while the options allow him to buy shares at a fixed $23.42 exercise price.

When do Mark Froimson’s new Pacira (PCRX) restricted stock units vest?

The 6,405 restricted stock units vest on June 10, 2027, provided Froimson remains in continuous service with Pacira. At vesting, each unit delivers one share of Pacira common stock, increasing his direct share ownership on that date.

What are the key terms of Mark Froimson’s new Pacira (PCRX) stock options?

Froimson’s 10,891 stock options have a $23.42 exercise price and vest on June 10, 2027, contingent on continuous service. Once vested, they are exercisable until June 10, 2036, giving a long window to purchase Pacira common shares.

How many Pacira (PCRX) common shares does Mark Froimson hold after these grants?

After the restricted stock unit grant, Froimson directly holds 26,541 shares of Pacira common stock. This figure reflects his updated non-derivative ownership as reported, separate from the additional 10,891 shares underlying his new stock options.

Are Mark Froimson’s Pacira (PCRX) awards tied to continued service?

Yes. Both the 6,405 restricted stock units and the 10,891 stock options require Froimson to remain in continuous service with Pacira until June 10, 2027. If that condition is met, the RSUs vest and the options become exercisable on that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 09:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Froimson Mark

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A		6,405(1)	A	$0	26,541	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.42	06/10/2026		A		10,891		06/10/2027(2)	06/10/2036	Common Stock	10,891	$0	10,891	D

Explanation of Responses:

1. Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

2. The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)